| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8787621 | Journal of Thoracic Oncology | 2018 | 21 Pages |
Abstract
Erlotinib plus tivantinib was tolerable and showed improved efficacy over erlotinib monotherapy in previously treated EGFR-mutant NSCLC.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Giorgio V. MD, Dale PhD, Sergey PhD, Joachim MD, Frances A. MD, Jeffrey S. MD, Qiang PhD, Brian MD, Wallace MD,